TNAX Biopharma Inc., in partnership with the University of Tsukuba, today announced the development of a new drug designed to prevent the progression of acute conditions, such as myocardial infarction and kidney injury, to chronic organ failure.
The joint research identified a novel compound that successfully suppresses organ fibrosis and preserves organ function in preclinical studies. TNAX Biopharma is now advancing this candidate towards clinical trials, aiming to provide a new therapeutic option for patients at risk of chronic organ disease.
*Ref(English)：https://www.tsukuba.ac.jp/en/research-news/20250819140000.html
*Ref(Japanese)：https://www.tsukuba.ac.jp/journal/medicine-health/20250819140000.html